[1]
Chen, C.; Chai, X.; Hu, X.; Lou, S.; Li, D.; Hou, T. Cui, S. Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1H-pyrazol-3-yl) acetamides as potent, selective, and orally available antagonists targeting the androgen receptor. J. Med. Chem., 2022, 65, 13074-13093.
[2]
Qi, J.; Wang, W.; Tang, Y.; Lou, S.; Wang, J.; Yuan, T.; He, Q.; Yang, B.; Zhu, H. Cui, S. Discovery of novel indazoles as potent and selective PI3K δ inhibitors with high efficacy for treatment of hepatocellular carcinoma. J. Med. Chem., 2022, 65, 3849-3865.
[3]
Zeng, L.; Li, J. Cui, S. Rhodium-catalyzed atroposelective click cycloaddition of azides and alkynes. Angew. Chem. Int. Ed., 2022, 61, e202205037.
[4]
Lai, Z.; Wu, R.; Li, J.; Chen, X.; Zeng, L.; Wang, X.; Guo, J.; Zhao, Z.; Sajiki, H. Cui, S. Multicomponent double Mannich alkylamination involving C(sp2)–H and benzylic C(sp3)–H bonds. Nat. Commun., 2022, 13, 435-442.
[5]
Lou, S. Cui, S. Drug treatment of epilepsy: from serendipitous discovery to evolutionary mechanisms. Curr. Med. Chem., 2022, 3366-3391.
